Eric Solomine is a corporate associate in the Boston office of Kirkland & Ellis LLP. His practice focuses on mergers, acquisitions and other transactions in the pharmaceutical and technology industries in the U.S. and internationally.
Experience
Representative Matters
Prior to joining Kirkland, Eric was involved in the following representative matters:
AspenTech in its $7.2 billion sale to Emerson of all shares of AspenTech not already owned by Emerson
The special committee of the board of directors of R1 RCM in its sale to investment funds affiliated with TowerBrook Capital Partners and Clayton Dubilier & Rice for an enterprise value of $8.9 billion
EyeBio in its sale to Merck for $1.3 billion up front and up to $1.7 billion in future milestone payments
Ambrx Biopharma in its $2 billion acquisition by Johnson & Johnson
The special committee of the board of directors of EngageSmart in its $4 billion sale to Vista Equity Partners
POINT Biopharma in its $1.4 billion acquisition by Eli Lilly
Clerk & Government Experience
Judicial InternHonorable George A. O’Toole, Jr.United States District Court for the District of MassachusettsSummer 2021
